GHK-Cu (Copper Peptide): Research, Mechanism, and Evidence for Tissue Repair

What it is

GHK-Cu is a tiny natural peptide, just three amino acids (glycine, histidine, and lysine), bound to a copper ion. Your body makes it, and it turns up in blood, saliva, and urine.

Loren Pickart found it in 1973 while studying why blood plasma from people in their early twenties made old liver tissue behave like young tissue. The active ingredient turned out to be this copper-peptide complex (Pickart, 2008).

Blood levels fall with age, from roughly 200 ng/mL at 20 to about 80 ng/mL at 60. That drop runs alongside slower tissue repair, which is what drew researchers to it. Whether putting levels back up rejuvenates anything in a living person has not been properly tested.

What it is studied for

The main uses studied are skin aging, as a cream; wound healing, mostly in animals; and hair growth, mostly in the lab. Researchers have also mapped how GHK-Cu changes gene activity, which has raised questions about lung disease and cancer that remain theoretical for now.

What the evidence actually shows

In humans

The best human evidence is for creams. In a 12-week facial study, a GHK-Cu cream improved skin laxity, clarity, and firmness and reduced fine lines and dark spots compared with the same cream without the peptide. Skin samples showed a thicker dermis, denser collagen fibers, and more active skin cells. In comparisons with retinol and vitamin C, GHK-Cu did as well or better at stimulating collagen (Leyden et al., 2002; Pickart et al., 2015).

These were small cosmetic studies, not drug trials. They are enough to call topical GHK-Cu one of the better-tested cosmetic peptides, and not enough to call it a proven treatment.

For hair, there are lab results and limited human observations, but no large trial (Pyo et al., 2007). We could not find a human trial of injected GHK-Cu for any purpose.

In animals

In rat wound studies, GHK-Cu applied to the skin sped up closure of both open wounds and surgical cuts. Treated wounds grew new skin faster, laid down more collagen, and formed less scar tissue with a more orderly structure. Wound chambers containing GHK-Cu drew in more immune and repair cells than controls (Leyden et al., 1987).

Wound healing is the most consistent animal finding, and it holds up across different research groups.

In the lab

The copper is not decoration. Several repair enzymes need copper to work, including lysyl oxidase, which cross-links collagen and elastin, and superoxide dismutase, a key antioxidant enzyme. GHK-Cu hands copper to tissue in a controlled form, without the toxicity of free copper (Pickart et al., 2012).

GHK-Cu also pushes cells to build the scaffolding of skin: collagen types I, III, and V, elastin, and the proteins that hold water in tissue. At the same time it regulates matrix metalloproteinases, the enzymes that break tissue down, switching on the ones needed for remodeling and reining in the ones that cause damage (Pickart et al., 2015).

Much of GHK-Cu’s reputation comes from gene studies. A Broad Institute analysis found it changed the activity of about 4,000 human genes, around 6% of the genome. Genes for collagen, DNA repair, and antioxidant defenses went up. Genes for inflammation, tissue breakdown, and cancer spread went down, and the overall pattern looked more like young tissue than old. The same analysis found that GHK’s pattern was close to a mirror image of the gene pattern seen in emphysema-damaged lung (Campbell et al., 2012).

That is a striking result, and it is a result about cells in a dish and data in a computer. A gene changing activity does not mean a person gets better. The cancer signal cuts the same way: GHK-Cu turns up tumor suppressor genes and turns down metastasis genes, which is reassuring, but no long-term cancer study exists.

From user reports

People who inject GHK-Cu say they do it for whole-body tissue repair or anti-aging rather than skin alone. They describe injection-site redness, occasional nausea, a metallic taste, and headaches. There is no study behind any of this.

How it is used in studies

The human skin studies used a GHK-Cu cream applied to the face over 12 weeks. Products on the market range from 0.01% to 1% GHK-Cu, applied once or twice a day, and users report visible changes at 8 to 12 weeks.

People who inject it report 1 to 2 mg per day, or 2 to 4 mg every other day, under the skin of the abdomen or near the target area, in cycles of 20 to 30 days on and 10 to 30 days off. This is user practice, not a studied dose. For general handling, see the storage and reconstitution guide.

Some cosmetic practices apply GHK-Cu serum right after microneedling at 0.5 to 1.5 mm depth, every 2 to 4 weeks, on the theory that the tiny channels help the peptide get in. We could not find a controlled study of this.

Side effects and unknowns

As a cream, GHK-Cu is well tolerated. Mild irritation happens occasionally, allergic reactions rarely, and decades of cosmetic use give it a reasonable track record.

Injection is a different question, and the question is copper. Copper is essential in small amounts and toxic in excess, and injection bypasses the gut’s controls on how much gets absorbed. Signs of excess include nausea, a metallic taste, and liver stress. Some users check blood copper during a cycle. Nobody has measured what months of injected GHK-Cu do to copper levels.

People with Wilson’s disease, a genetic disorder in which copper builds up in the body, should avoid it. So should anyone with a known copper allergy. There is no safety data for pregnancy or breastfeeding. See our peptide safety guide for general monitoring.

Legal status

In the United States, GHK-Cu is not FDA approved as a drug for any use. It is legal in creams and serums, because cosmetics are regulated differently from drugs. Compounding pharmacies may prepare injectable GHK-Cu.

Elsewhere it is generally unregulated in cosmetics, and the injectable form falls under research chemicals. GHK-Cu is not on the WADA Prohibited List.

Bottom line

Topical GHK-Cu has small but real human evidence for aging skin, and a good safety record in creams. Injected GHK-Cu has animal and lab data, user reports, and an open question about copper. The gene-expression findings are intriguing and prove nothing yet about outcomes in people.

Frequently Asked Questions

Is topical GHK-Cu sufficient, or are injections necessary?

For skin, topical use is the better-evidenced route. Some people inject it hoping for whole-body effects, but the evidence for that is much thinner.

Is GHK-Cu safe for people with copper IUDs or copper-rich diets?

A cream delivers almost no copper to the bloodstream. Injections add a small amount, probably minor next to a normal diet, but worth raising with a doctor if your copper intake is already high.

How does GHK-Cu compare to retinol for anti-aging?

They work differently. Retinol acts through retinoic acid receptors; GHK-Cu acts through copper and broad gene changes. Some dermatologists suggest alternating or combining them.

Could GHK-Cu promote cancer?

The gene data point the other way, with tumor suppressor genes up and metastasis genes down. No long-term cancer study has been done, so the question stays open.

How does GHK-Cu compare to other healing peptides like BPC-157?

BPC-157 is studied for new blood vessel growth and growth-factor signaling in acute injury. GHK-Cu is studied for tissue remodeling and collagen quality. Our injury recovery guide compares them in detail.

Is the age-related decline in GHK-Cu levels clinically meaningful?

The drop from about 200 ng/mL at 20 to about 80 ng/mL at 60 lines up with slower repair. Whether topping levels back up reverses anything in a person has not been tested in controlled trials.

References

1. Pickart L. “The human tri-peptide GHK and tissue remodeling.” J Biomater Sci Polym Ed. 2008;19(8):969-88. PubMed
2. Pickart L, et al. “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.” Biomed Res Int. 2015;2015:648108. PubMed
3. Pickart L, et al. “GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes.” Cosmetics. 2012;2(3):236-247. PubMed
4. Campbell JD, et al. “A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK.” Genome Med. 2012;4(8):67. PubMed
5. Leyden JJ, et al. “Skin care benefits of copper peptide containing facial cream.” Proc Am Acad Dermatol. 2002. Related: PubMed
6. Pyo HK, et al. “The effect of tripeptide-copper complex on human hair growth in vitro.” Arch Pharm Res. 2007;30(7):834-9. PubMed
7. Siméon A, et al. “Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+).” J Invest Dermatol. 2000;115(6):962-8. PubMed

See also

• Peptide
  BPC-157: What the Research Actually Shows About This Healing Peptide

  A plain review of the animal research on BPC-157, what it suggests about healing, and why none of it has been confirmed in people.

• Peptide
  Epithalon (Epitalon): Research, Mechanism, and a Careful Look at the Anti-Aging Evidence

  Epithalon is a four-amino-acid peptide from a Russian lab, studied for switching on telomerase and restoring melatonin. It lengthened telomeres in a dish and extended lifespan in mice, and it has never been tested for aging in people.

• Peptide
  FOXO4-DRI: What the Research Shows About This Senolytic Peptide

  FOXO4-DRI is a designed peptide that pushes senescent cells, the worn-out cells that linger and cause inflammation, into dying. One 2017 mouse study showed remarkable rejuvenation. It has never been repeated or tested in people.